- Conditions
- Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Multiple Myeloma
- Interventions
- cyclophosphamide, cyclosporine, Fludarabine, mycophenolate mofetil, total marrow irradiation, umbilical cord blood transplantation, Granulocyte colony-stimulating factor, HLA-matched related donor bone marrow
- Drug · Radiation · Procedure + 1 more
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 313–336
of 17,839
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy
- Interventions
- Efavirenz, Bupropion, Rosuvastatin, Montelukast
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Waldenstrom Macroglobulinemia
- Interventions
- Pirtobrutinib, Venetoclax
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2033
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Clostridium Difficile Associated Disease
- Interventions
- Clostridium difficile Vaccine, Placebo
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 65 Years to 85 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2020
- U.S. locations
- 17
- States / cities
- DeLand, Florida • Hollywood, Florida • South Miami, Florida + 11 more
- Conditions
- Prostate Cancer
- Interventions
- Aplidin (plitidepsin)
- Drug
- Lead sponsor
- PharmaMar
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Seattle, Washington
- Conditions
- Kaposi Sarcoma
- Interventions
- liposomal doxorubicin, pomalidomide
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2029
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Low Back Pain
- Interventions
- Hydromorphone ER, Sugar pill
- Drug
- Lead sponsor
- Shirley Ryan AbilityLab
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Recurrent Ependymoma
- Interventions
- 5-Azacytidine (5-AZA) group 1, 5-Azacytidine (5-AZA) group 2, 5-Azacytidine (5-AZA) group 3
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 1 Year to 80 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hepatitis C
- Interventions
- Glecaprevir/pibrentasvir
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 16 Years to 45 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Aurora, Colorado • Jacksonville, Florida + 5 more
- Conditions
- Chronic Lymphocytic Leukemia, Lymphomas, Leukemias
- Interventions
- ABT-263
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 5
- States / cities
- Encinitas, California • Santa Monica, California • Bethesda, Maryland + 2 more
- Conditions
- Dry Eye Disease
- Interventions
- Lifitegrast/Perfluorohexyloctane Fixed Dose Combination, Lifitegrast, Perfluorohexyloctane, Vehicle
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 443 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Glendale, California • Long Beach, California + 27 more
- Conditions
- Dry Eye Disease
- Interventions
- AG-80308
- Drug
- Lead sponsor
- Allgenesis Biotherapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 3
- States / cities
- Newport Beach, California • Raynham, Massachusetts • Clinton, Utah
- Conditions
- Acute Ischemic Stroke
- Interventions
- High-definition Cathodal Transcranial Direct Current Stimulation (HD C-tDCS), Sham tDCS
- Device
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Baltimore, Maryland • Durham, North Carolina
- Conditions
- Healthy Participants
- Interventions
- Elecoglipron, Atorvastatin, Rosuvastatin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Glendale, California • Brooklyn, Maryland
- Conditions
- Solid Tumor, Adult
- Interventions
- ASTX029
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 19
- States / cities
- Duarte, California • Los Angeles, California • Newport Beach, California + 13 more
- Conditions
- Safety
- Interventions
- SBT115301, Placebo
- Biological
- Lead sponsor
- Sonoma Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Chronic Fatigue Syndrome, Orthostatic Intolerance, Postural Tachycardia Syndrome
- Interventions
- Autonomic Function Testing, Saline infusions, L-NMMA trimethaphan, methyldopa
- Other · Drug
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2017
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Contraception
- Interventions
- Testosterone, Nestorone®
- Drug
- Lead sponsor
- Premier Research
- Other
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 99 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 2
- States / cities
- Torrance, California • Seattle, Washington
- Conditions
- Rheumatoid Arthritis
- Interventions
- INCB028050, Placebo
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 38 more
- Conditions
- Ewing's Family Tumors, Renal Tumors, Hepatoblastoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Primary Malignant Brain Neoplasms, Retinoblastoma, Medulloblastoma, Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET), Atypical Teratoid/Rhabdoid Tumor (AT/RT), CNS Tumors, Germ Cell Tumors
- Interventions
- Ifosfamide, Etoposide, Mesna, G-CSF, Busulfan, Melphalan, Thiotepa, Autologous stem cell infusion, Radiation, Carboplatin, Paclitaxel, Leukapheresis, Anti-seizure prophylaxis, Ursodiol
- Drug · Biological · Radiation + 1 more
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2024
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Advanced Non Small Cell Lung Cancer
- Interventions
- Part A - AZD9291 in combination with AZD6094, Part A - AZD9291 in combination with continuous selumetinib (Asian subjects), Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects), Part A - AZD9291 in combination with intermittent selumetinib, Part A - AZD9291 in combination with MEDI4736, Part B - AZD9291 in combination with AZD6094, Part B - AZD9291 in combination with selumetinib, Part B - AZD9291 in combination with MEDI4736, Part C - AZD6094 monotherapy (Japan only), Part C - AZD9291 in combination with AZD6094 (Japan only), Part D - AZD9291 in combination with AZD6094
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • New York, New York + 2 more
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- Ontak
- Drug
- Lead sponsor
- Loyola University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Maywood, Illinois
- Conditions
- Advanced Cancers, DLBCL, Lymphoma
- Interventions
- IONIS-STAT3Rx
- Drug
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 9
- States / cities
- Scottsdale, Arizona • La Jolla, California • New Haven, Connecticut + 6 more
- Conditions
- Acute Coronary Syndrome
- Interventions
- Losmapimod, Moxifloxacin, Losmapimod matched Placebo, Moxifloxacin Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland